Why the study?
What is the optimal perioperative management of anticoagulant or antiplatelet therapy in patients undergoing noncardiac surgery?
What is the optimal perioperative management of anticoagulant or antiplatelet therapy in patients undergoing noncardiac surgery?
This review provides a practical, evidence-based framework for managing the complex balance of bleeding and thrombotic risks in patients on antithrombotic therapy undergoing noncardiac surgery.
Answers are grounded in this paper and cite their sources.
No study data available; leaves open optimal perioperative antithrombotic management in noncardiac surgery.
Patients receiving anticoagulant or antiplatelet therapy who require noncardiac surgery represent a common yet challenging clinical problem. Clinicians must balance the risk of thromboembolic and major adverse cardiovascular events that are associated with interrupting these therapies, against the risk of bleeding from continuing these drugs in the perioperative period. Identifying patients at highest risk for such complications requires particular attention to the role of bridging therapy and the optimal timing and duration of drug withdrawal and resumption with surgery. Patients with coronary stents represent a population that requires specific considerations, due to the added risk and significant mortality associated with perioperative stent thrombosis. Minimizing this risk is dependent on several patient- and stent-specific factors. This review provides clinicians with a summary of the available evidence to facilitate a practical approach to the management of these patients while highlighting the need for continued research in this field.
No takes yet. Share an insight, caveat, or question.
Darvish‐Kazem et al. (2012) studied Perioperative Management of Patients Having Noncardiac Surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: